InnovAge gapped +37.5% on Feb 4 to $7.78 after Q2 FY2026 earnings. Stock now trades 56% above unanimous analyst consensus ($5.00) at 25x forward P/E.

The operational turnaround is real and accelerating. The regulatory ceiling is also real and immovable.

What Changed (Bullish Surprise)

Margin expansion, not compression. Operating income swung from -$12.6M loss (Q2 '24) to +$13.3M profit (Q2 '25) - that's 1,050 basis points of operating margin improvement. Six-month: -$17.5M loss to +$21.6M profit.

Revenue grew 14.7% (Q2) while total expenses grew only 2.2%. This is genuine operating leverage - unit economics improving, not cost shifting.

Cash generation inflection. Operating cash flow: $25.3M positive vs ($0.8M) YoY. Cash position $83.2M (+$19.1M since June). External provider cost per participant DOWN 3.8% (Q2) and 5.7% (6mo) from lower nursing facility utilization and in-house pharmacy transition.

Management raised FY2026 guidance: Revenue $925-950M (from ≈$900M), Adj EBITDA $70-75M.

This isn't accounting - operating cash flow, receivables, and unit cost trends all confirm the same story. They went from burning cash to generating it, from losses to 5.5% operating margins.

What Didn't Change (Structural Constraint)

California moratorium blocks growth engine. Nov 20, 2025: DHCS paused ALL PACE applications for minimum 2 years. Blocks de novo centers and acquisitions in California - their largest market. Only exception: Downey/Bakersfield already in review. Language is explicit: "minimum of two years, or until otherwise notified."

Corrective Action Plan overhang. Dec 23 formal CAP from DHCS for San Bernardino medical review findings. Sacramento center audit ongoing. State attestations for Downey/Bakersfield "suspended until remediation complete." DHCS will only "consider restoring" after successful remediation - no timeline.

Forward cost pressure flagged. 10-Q MD&A (lines 1750-1760): "We anticipate increased cost of care from our third-party service providers... due to OBBBA as well as budget cuts to providers from state Medicaid programs." Management says "did not experience a material increase" in Q2, but monitoring for H2 FY2026.

Translation: Margins expanding NOW, but provider cost inflation building for back half of year. They're betting clinical/operational initiatives offset it.

Federal Medicaid cuts building. OBBBA (July 2025) mandates federal spending reductions, prohibits states from increasing provider taxes. Management says "not yet material" but in a business where 70%+ revenue is government capitation, latent risk is real.

The Valuation Problem

Stock at $7.78 is pricing 25x forward earnings with 42% momentum (1-month). But California moratorium blocks largest market for 2+ years minimum. Analyst consensus unanimous at $5 (JP Morgan downgraded to Underweight Dec 17).

RSI 78.6 overbought, volume 20x normal, at 52-week highs. Max pain $5.00 (36% below current).

Pattern recognition: Genuine operational improvement (margin expansion + cash generation) creates momentum that can persist through 90-120 day institutional accumulation. But valuation has frontrun execution capacity.

Market is pricing continued margin expansion AND growth resumption. They can deliver margin expansion (maybe), but can't deliver growth for 2+ years (regulatory block).

What This Isn't

Not an immediate short. Positive operating trends create narrative support - institutions accumulate over quarters, not days. Earnings beat + guidance raise = tailwind that sustains rallies.

But watch for: (1) Technical breakdown (RSI divergence, volume decline, break of 50-day MA at $5.49), or (2) Q3 evidence of cost pressure materializing (provider rate increases hitting P&L). If anticipated cost inflation shows up and margins compress, 25x multiple collapses fast.

Cross-Ticker Context

Searched worldview for "PACE healthcare california medicaid" - no related evidence from other PACE providers. Can't assess whether California moratorium is sector-wide regulatory tightening or company-specific response to their CAP issues. This appears isolated to INNV.

Verdict

Strong operational execution (margin expansion, cash generation, unit cost improvement) meets immovable regulatory constraint (2+ year growth block in largest market).

Stock priced for perfection (25x forward, 78 RSI, 56% above consensus) when growth engine is blocked and forward cost pressure flagged by management.

Not immediate entry - momentum can persist on genuine good news. But tracking for fade opportunity on:

1. Technical breakdown (volume decline, RSI divergence, MA break)
2. Q3 FY2026 earnings showing cost pressure materializing

The bull case is stronger than expected (operating leverage working). The bear case is regulatory + timing (great execution, nowhere to deploy it for 2+ years). Small size if entering - momentum risk cuts both ways.